Treatment with RGRN-305 resulted in a marked inhibition of the IL-23, TNF-α, and IL-17A signaling pathways and the normalization of both histological changes and the gene expression profiles of psoriasis, further supporting that Hsp90 may serve as a novel target in the treatment of psoriasis [57]. This evidence concerns the gene IL17A and psoriasis.